DSM Receives European Outsourcing Award For Carbon Footprint Reducing Technology

DSM Pharmaceutical Products' submission for the European Outsourcing Awards entitled "Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate," was an award recipient at the Oct. 6 ceremony held in Paris.

DSM applied their InnoSy route scouting services to launch a collaborative research program to identify a faster route for a drug intermediate using (bio)catalytic processes with the same level of reliability and quality, yet with a reduced carbon footprint of over 50%. The new process resulted also in shorter cycle times due to fewer steps in the process.

André de Vries, Ph.D., competence manager for Homogeneous Catalysis at DSM, commented, "This project involved scientists covering all relevant areas of organic process development, including biocatalysis and homogeneous catalysis. From the 10 new identified routes, all less than five steps, the route combining a biocatalytic and a metal-catalyzed step showed to be most sustainable. In this way, DSM as the contract manufacturer is contributing to extending the life cycle of the customer's product using innovation to decrease the eco footprint."

Company

DSM Pharmaceutical Products

45 Waterview Blvd.
Parsippany, NJ 07054-1298

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.